CD8A and neoplasm: Moreover, the improved tumor growth control achieved in the PeptiCRAd1 group correlated with the upregulation of the migratory marker CXCR4 in the CD8+ T-cell population in both treated and untreated tumors (Figure 8C) and upregulation of effector marker CXCR3 in the CD8+ T-cell population in the treated lesions (Figure 8D).